Science & Evidence
Publications & Outcomes
BioXcellerator's scientific credibility is built on a decade of real-world outcomes data, 13 published works, and a systematic approach to evidence generation that no competitor in the category has replicated.
Why Evidence Matters
The Evidence Advantage
The regenerative medicine category is filled with operators making claims that are not supported by evidence. BioXcellerator made a deliberate decision from the beginning to invest in evidence generation — not because it was required, but because it was the right thing to do for patients and the only path to building a credible, defensible platform.
The result is 13 published works, a 97% patient satisfaction rate across 50,000+ treatments, and an outcomes database that is the most comprehensive in the category. This evidence base serves multiple strategic purposes: it validates the clinical protocols, it builds physician confidence in the products, it creates publishable IP, and it differentiates BioXcellerator from every competitor that relies on anecdote rather than data.
As the category matures and regulatory scrutiny increases, the operators with evidence will survive and thrive. The operators without it will not. BioXcellerator has been building this advantage for a decade.
Selected Publications
Wharton's Jelly Mesenchymal Stem Cells in Orthopedic Applications: A Systematic Review
Halpert K., Silva F., et al.
Systematic review of 847 patients treated with WJ-MSC protocols across orthopedic indications. Primary outcomes: 78% reduction in pain scores, 71% improvement in functional mobility at 12 months.
Exosome-Based Therapy for Neurological Conditions: Clinical Outcomes in a Cohort of 312 Patients
Silva F., Halpert K., et al.
Prospective cohort study examining EVOKE Exosome therapy in neurological conditions. 68% of patients reported clinically meaningful improvement in primary outcome measures at 6-month follow-up.
Safety Profile of Placental-Derived Mesenchymal Stem Cell Therapies: A 5-Year Retrospective Analysis
Halpert K., et al.
5-year retrospective analysis of 12,000+ treatments. Adverse event rate: 0.3%. Serious adverse event rate: 0.02%. No treatment-related fatalities. Establishes the safety profile of the BioXcellerator protocol library.
Autoimmune Conditions and Mesenchymal Stem Cell Therapy: Outcomes in 450 Patients
Silva F., et al.
Multi-condition study of WJ-MSC therapy in autoimmune disorders. 73% of patients achieved clinically significant reduction in inflammatory markers. 65% reported improved quality of life at 12 months.
Quantum MU53 Cells Platform: Development, Characterization, and Clinical Validation
Silva F., Halpert K., Stoffers E., et al.
Comprehensive characterization of the Quantum MU53 Cells platform including manufacturing process, quality specifications, and clinical validation across 8 therapeutic areas.
Full Publication Library Available in the Deep Dive Data Room
All 13 published works, the complete outcomes database, and the Health Advisory Board's scientific review are available in the Deep Dive Data Room for approved investors.